Verve Therapeutics, Inc.. has placed 14 035 789 shares of common stock im an IPO priced $19 per share, that is $1 higher than the upper limit of the previously announced range ($16-18). Besides, Verve has granted the underwriters a 30-day option to purchase up to 2 105 368 shares at the public offering price.
The trading debut will take place on the Nasdaq Global Select Market on June 17, 2021 under the ticker symbol “VERV”.